Skip to Main ContentSkip to FooterSkip to Search
Main menu
  1. Home
  2.  » 
  3. Events
  4.  » Bio Process International East
Icon of a monthly calendar

Bio Process International East

Each year, more than 3200+ bioprocessing professionals representing 40+ countries attend BioProcess International in Boston to learn about today’s innovative science across the entire spectrum of biopharmaceutical development and production.

The exhibition features 250+ exhibitors showcasing novel technologies designed to accelerate biologics from process development through to commercial manufacturing.

Date: September 23-26, 2024
Location: Hynes Convention Center, Boston, MA
Booth: #1706

BioProcess International Logo

JOIN US!

From early phase development through clinical supply and commercial manufacturing, Catalent is committed to partnering with you to successfully bring your product to market. We invite you to join us at NLSDays to learn more about our integrated solutions that can help progress your candidate toward the clinic and on to commercial success.

Complete the form to schedule a meeting with Catalent experts at Bio Process International East!

FEATURED SPEAKING SESSIONS

Title: Practical Approaches to Characterizing Charged Variants
Date: Tuesday, September 24, 2024
Time: 1:00-1:45 PM EDT
Speaker: Shawn Fitzgibbons, Manager, Biologics, Catalent Kansas City

Title: Process characterization: Standardized Workflow to Support Process Validation
Date: Thursday, September 26, 2024
Time: 12:15-12:45 PM EDT
Speaker: Wai Lam Ling, Ph.D., VP Scientific Advisory, Catalent

SPEAKERS

Shawn Fitzgibbons Headshot

Shawn Fitzgibbons
Manager, Biologics
Catalent Kansas City

Wai Lam Ling headshot

Wai Lam Ling, Ph.D.
Vice President
Scientific Advisory
Catalent

ABOUT CATALENT BIOLOGICS

For nearly three decades, Catalent Biologics has built capabilities and expertise in development, manufacturing, and analytical services, now spanning new biological entities, biosimilars, plasmid DNA, cell and gene therapies, vaccines, sterile injectables, mRNA, and antibody-drug conjugates. It has developed 600+ antibodies and 80+ recombinant proteins, with more than 120 active clinical trials and 16 marketed biotherapeutics use GPEx® cell line engineering technology. More than 45 commercially approved products have employed Catalent Biologics’ manufacturing and packaging capabilities.

Using advanced technologies and tailored solutions from clinical to commercial supply, Catalent brings better biologic and advanced treatments to patients, faster.

Related Topics

We Are Looking Forward To Seeing You In Boston!